Quantitative analysis of buprenorphine and norbuprenorphine in urine using liquid chromatography tandem mass spectrometry

Journal of Analytical Toxicology

Volumn 30, Issue 4, 2006, Pages 238-244

  Fox, E J ^a   Tetlow, V A ^b   Allen, K R ^a  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^b HOPE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCURONIDASE; BUPRENORPHINE; DRUG METABOLITE; NORBUPRENORPHINE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; NARCOTIC ANALGESIC AGENT;

ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG URINE LEVEL; GAS CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; LIQUID CHROMATOGRAPHY; MOLLUSC; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; EVALUATION; HEROIN DEPENDENCE; MASS SPECTROMETRY; METHODOLOGY; URINE;

ANALGESICS, OPIOID; BUPRENORPHINE; CHROMATOGRAPHY, LIQUID; HEROIN DEPENDENCE; HUMANS; MASS SPECTROMETRY;

EID: 33747203249     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/30.4.238     Document Type: Article

References (19)

1. Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment improvement protocol (TIP) series 40. DHHS publication no. (SMA) 04-3939. Substance Abuse and Mental Health Services Administration, Rockville, MD, 2004. http://www.kap.samhsa.gov/products/manuals/index.htm (Accessed January 2005)
2. E.J. Cone, C.W. Gorodetzky, D. Yousefnejad, W.F. Buchwald, and R.E. Johnson. The metabolism and excretion of buprenorphine in humans. Drug Metab. Dispos. 12: 577-581 (1984).
3. K. Kobayashi, T. Yamamoto, K. Chiba, M. Tani, N. Shimada, T. Ishizaki, and Y. Kuroiwa. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab. Dispos. 26: 818-821 (1998).
4. D. Brewster, M.J. Humphrey, and M.A. McLeavy. Biliary excretion, metabolism and enterohepatic circulation of buprenorphine. Xenobiotica 11: 189-196 (1981).
5. P. Kintz, A. Tracqui, P. Mangin, and Y. Edel. Sweat testing in opioid users with a sweat patch. J. Anal. Toxicol. 20: 393-397 (1996).
6. M. Deveaux, P. Kintz, J.P. Goulle, J. Bessard, G. Pepin, and D. Gosset. The hair analysis proficiency testing program of the French society of analytical toxicology. Forensic Sci. Int. 107: 389-394 (2000).
7. T. Gunnar, K. Ariniemi, and P. Lillsunde. Validated toxicological determination of 30 drugs of abuse as optimized derivatives in oral fluid by long column fast gas chromatography/electron impact mass spectrometry. J. Mass Spectrom. 40: 739-753 (2005).
8. Y. Blom, U. Bondesson, and E. Anggard. Analysis of buprenorphine and its n-dealkylated metabolite in plasma and urine by selected-ion monitoring. J. Chromatogr. B 338: 89-98 (1985).
9. R.A. Jenkinson, N.C. Clark, C.L. Fry, and M. Dobbin. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction100: 197-205 (2005).
10. R. Hammersley, M.T. Cassidy, and J. Oliver. Drugs associated with drug-related deaths in Edinburgh and Glasgow, November 1990 to October 1992. Addiction90: 959-966 (1995).
11. S. George, C. George, and M. Chauhan. The development and application of a rapid gas chromatography-mass spectrometry method to monitor buprenorphine withdrawal protocols. Forensic Sci. Int. 143: 121-125 (2004).
12. A.M. Lisi, R. Kazlauskas, and G.J. Trout. Gas chromatographic-mass spectrometric quantitation of urinary buprenorphine and norbuprenorphine after derivatization by direct extractive alkylation. J. Chromatogr. B 692: 67-77 (1997).
13. M. Pavlic, K. Libiseller, P. Grubwieser, and W. Rabl. Cross-reactivity of the CEDIA buprenorphine assay with opiates: an Austrian phenomenon? Int. J. Legal Med. 119(6): 378-381 (2005).
14. R. Kronstrand, T.G. Selden, and M. Josefsson. Analysis of buprenorphine, norbuprenorphine, and their glucuronides in urine by liquid chromatography-mass spectrometry. J. Anal. Toxicol. 27: 464-470 (2003).
15. J. Combie, J.W. Blake, T.E. Nugent, and T. Tobin. Morphine glucuronide hydrolysis: superiority of β-glucuronidase from patella vulgata. Clin. Chem. 23: 83-86 (1982).
16. Guidance for Industry: Bioanalytical Method Validation. U.S. Department of Health and Human Services, Food and Drug Administration, 2001. http://www.fda.gov/cder/guidance/index.htm
17. J.O. Westgard. Method validation - the interference and recovery experiments. http://www.westgard.com/lesson27.htm, August 2005.
18. L. Gowing, R. Ali, and J. White. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst. Rev. 4: CD002025 (2004).
19. C.M. Murphy and M.A. Huestis. Liquid chromatographic/electrospray ionization tandem mass spectrometric analysis for the quantification of buprenorphine, norbuprenorphine, buprenorphine-3-D-glucuronide in human plasma. J. Mass Spectrom. 40: 70-74 (2005).